Focus on prostate cancer  by Isaacs, William et al.
F O C U S
CANCER CELL : AUGUST 2002 · VOL. 2 · COPYRIGHT © 2002 CELL PRESS 113
Focus on prostate cancer
William Isaacs,1,4 Angelo De Marzo,2 and William G. Nelson3
1Department of Urology
2Department of Pathology 
3Department of Oncology
The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
4Correspondence: wisaacs@jhmi.edu
Introduction and clinical epidemiology
In 1990, prostate cancer surpassed lung cancer as the most
common noncutaneous malignancy diagnosed in men in the
U.S. This year prostate cancer will be responsible for over
31,000 deaths in this country, resulting in an annual loss of
almost 300,000 years of life. The incidence of prostate cancer
shows strong age, race, and geographical dependence. Less
than 1% of cases are diagnosed under the age of 40, although
this may represent an underestimate as screening for disease
in young men is rare. Prostate cancer is relatively uncommon in
Asian populations and prevalent in Scandinavian countries, and
the highest incidence (and mortality) rates known are in African
Americans, being ~2-fold higher than in Caucasian Americans
(Figure 1). Mortality rates vary significantly by country, ranging
from over 32 per 100,000 in Trinidad, to 23 per 100,000 for
Caucasians in the U.S., to 4 per 100,000 in Japan (Boring et al.,
1992).
Like most common cancers, the etiologic factors associated
with prostate cancer are varied, encompassing both host genet-
ic and environmental influences. Environmental factors are
clearly indicated by migration studies; e.g., large increases in
risk in Japanese men occur when they move to the United
States. Etiologic factors include aging, familial clustering, race,
hormonal influences, diet (both inductive and preventive fac-
tors), and lifestyle factors (Hsing and Devesa, 2001). Age, famil-
ial clustering, and race are clearly important, well-documented
risk factors, and dietary influences such as red meat, high fat
(elevated risk), antioxidants (e.g., selenium, lycopene [lowered
risk]), and hormone levels are most likely critical factors as well.
The finding of increased risk associated with increased serum
levels of insulin-like growth factor 1 (IGF-1) (Chan et al., 1998)
is an example clearly implicating nonandrogenic growth regula-
tory pathways as potentially important in determining prostate
cancer risk.
Natural history and diagnostics
The initiation of prostate cancer, i.e., the formation of a histolog-
ically identifiable lesion, is a common event, being detected at
autopsy series in nearly one-third of men over age 45.
Fortunately, the majority of such lesions do not progress to clin-
ically detectable tumors within the lifetime of these men.
Clinically, prostate cancers are diagnosed upon histological
evaluation of needle biopsy samples of prostate tissue, taken
because of an abnormal physical examination, an elevated
serum PSA level, or both. Due to the common morphological
heterogeneity of prostate cancer, two different grades are given
for the first and second most prevalent patterns, and the sum of
these two grades is added to give the Gleason score. Staging is
categorized using a TNM (tumor, node, metastasis) classifica-
tion, with lymph nodes and bone being the most common sites
of metastatic spread. Prostate cancer develops in two different
regions of the gland, with most lesions (?80%) being found in
the periphery, and most of the remaining cancers found in a
periurethral region termed the transition zone. Curiously, the vir-
tually ubiquitous process of benign prostatic hyperplasia (BPH)
originates in the transition zone of the prostate (McNeal, 1978).
Based primarily on this regional difference in the incidence of
benign and malignant growth, and the fact that stromal cell pro-
liferation is typically a major component of BPH, these benign
lesions are not thought to be the precursors of invasive adeno-
carcinoma in the prostate. Instead, prostatic intraepithelial neo-
plasia, or PIN, is the term given to characteristic foci of dysplas-
tic ductal and acinar cells thought to be the precursor lesions of
this disease (Bostwick, 1989).
Prior to the widespread study of PIN, various atrophic
lesions have been described as potential prostate cancer pre-
cursors. More recently, this notion has become reinvigorated,
since focal “atrophy” lesions are highly proliferative, occur pre-
dominantly in the peripheral zone, are found at times to merge
directly with high-grade PIN, are often found near small can-
Figure 1. SEER incidence and mortality rates for prostate cancer in the U.S.
Regression lines are calculated using the Joinpoint regression program. +,
White; X, Black; @, Hispanic; *, Asian/Pacific Islander; 6, American
Indian/Alaskan Native.
A: Source: SEER 12 areas (San Francisco, Connecticut, Detroit, Hawaii,
Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles,
and Alaska). Incidence data for Hispanics does not include cases from
Detroit and Hawaii.
B: Source: NCHS public use data file. Mortality data for Hispanics does not
include cases from Connecticut, Oklahoma, New York, and New
Hampshire. Mortality data from all other races are from all U.S. states.
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cers, and at times have genetic alterations similar to those
detected in high-grade PIN and adenocarcinoma (reviewed in
De Marzo et al., 2001). Since these atrophy lesions are usually
associated with an inflammatory component and exhibit pheno-
typic signs of incurring oxidant stress, they have been termed
proliferative inflammatory atrophy (PIA). It has been suggested
that similar to other major epithelial cancers, such as those in
the liver and stomach, inflammatory cell mediated oxidant
stress may be a key pathogenetic mechanism driving prostate
carcinogenesis (De Marzo et al., 2001).
Prostate cancer is commonly multifocal, e.g., the prostate of
a man diagnosed with prostate cancer contains an average of 5
apparently independent cancer lesions and many more high-
grade PIN lesions (Bastacky et al., 1995). These lesions are
genetically heterogeneous, both inter- and intratumorally; inter-
estingly, this multifocality is independent of family history of
prostate cancer (Bastacky et al., 1995). The tendency for
prostate cancers to have a long natural history is emphasized
by tumor doubling times often measured in months and years
(Berges et al., 1995), although there are certainly exceptions.
The introduction of serum prostate-specific antigen (PSA)
as a screening tool is primarily responsible for the >2-fold
increase in incidence rates observed between 1986 and 1992
(Stanford et al., 1999), as well as the substantial decline in the
percentage of cases diagnosed annually with disseminated dis-
ease. The absolute mortality rates for prostate cancer declined
in the U.S. for the first time in 1995 (Stanford et al., 1999), most
likely as a result of early detection and treatment resulting from
increased screening, although there is debate over this issue.
PSA is a serine protease with a chymotrpysin-like substrate
specificity, which is normally secreted by the prostate in large
amounts into the seminal plasma, with only small amounts
entering the bloodstream. While highly elevated serum PSA lev-
els are most often associated with prostate cancer, a current
focus of intense research effort is on the ability to accurately
interpret moderately elevated PSA levels (e.g., 4–10 ng/ml),
which can be indicative of either benign or malignant disease
(reviewed in Bunting, 2002). The measurement of more cancer-
specific forms of PSA offers the promise of discrimination to
address this problem. Interestingly, baseline PSA levels in
young men are strong predictors of the likelihood of eventual
prostate cancer diagnosis (Fang et al., 2001).
While PSA is a useful tool for screening for prostate cancer
and as a monitor of disease progression after therapy, it is not
as useful in determining prognosis. In fact, the inability to deter-
mine, at diagnosis, which prostate cancers will progress or
already have progressed to disseminated disease is one of the
foremost problems in the clinical management of this disease.
This problem in staging prostate cancer accurately is empha-
sized by two observations: (1) between 15% and 40% of men
who are thought to have clinically localized disease at diagnosis
in fact have disseminated disease, for which there is currently
no curative treatment; and (2) a substantial but unknown frac-
tion of prostate cancers will not progress or will progress so
slowly that they pose little threat to the patients in whom they
are diagnosed. New prognostic indicators and methodologies
that can assist in these distinctions are urgently needed.
Therapeutics and androgen independence
Early stage prostate cancer is typically treated with either surgi-
cal removal or localized radiotherapy, and in some cases is just
followed without treatment (“watchful waiting”).
The effectiveness of these treatments, while still largely
unproven, is suggested by decreasing mortality rates observed
over the past several years. Increasing serum PSA levels after
prostatectomy or other treatment for prostate cancer is a very
reliable indication of disease progression, although the develop-
ment of clinically detectable metastases typically takes years to
become apparent (Pound et al., 1999).
The prostate gland is an androgen-dependent organ, and
thus undergoes involution upon androgen deprivation. Similarly,
prostate cancers generally respond to androgen ablation, trig-
gering programmed cell death and forming the basis for the
most common therapies currently used for treatment of
advanced prostate cancer. Although very effective in a palliative
sense, such androgen ablation therapy is almost never curative,
as the disease invariably progresses to an androgen-indepen-
dent state. This transition to a hormone refractory stage
remains a foremost challenge, both therapeutically and experi-
mentally (Feldman and Feldman, 2001). While the mechanisms
underlying this transition are not fully understood, significant
progress has been made in this area. Molecular mechanisms
implicated in progression to androgen independence include
AR gene amplification, steroid coactivator upregulation, AR
mutations which alter ligand specificity and/or sensitivity (most
commonly seen in patients on long term antiandrogen therapy),
and altered dependence upon nonandrogen mediated growth
factor and signaling pathways (e.g., ErbB2 and NFκB [Chen
and Sawyers, 2002]).
Current clinical challenges include the development of
methodologies to more effectively stage prostate cancer
(including development of more informative and sensitive imag-
ing modalities), definition of better prognostic markers, particu-
larly ones that are least effected by sampling bias, and efficient
treatments for advanced, hormone refractory disease.
Promising advances in this last area include prostate replication
restricted adenoviruses (Rodriguez et al., 1997), cytotoxic drug
activation by PSA (i.e., prodrug therapy) (Denmeade et al.,
1998), antibodies targeted at prostate-specific membrane anti-
gen (PSMA) (Gong et al., 1999), and signal transduction
inhibitors which target PTEN null cells (Neshat et al., 2001).
Genetics of sporadic and familial prostate cancer
As with other commons adenocarcinomas, both numerical and
structural chromosomal alterations are frequent somatic
changes in prostate cancer cells. The most frequently affected
chromosomes are 8, 10, 13, 16, and 17 (for review see Isaacs
and Kainu, 2001). Loss of 8p appears to be an early event in
prostate cancer development, since prostate intraepithelial neo-
plasia frequently shows LOH at this location, and more recently,
chromosome 8 alterations have been detected in PIA. However,
no unequivocal candidates for the specific genes involved have
appeared, although several genes, including NKX3.1 and
LZTS, are promising.
Clearly, the initiating somatic genetic alterations driving
prostate cancer development still remain to be uncovered.
Intriguingly, hypermethylation of the glutathione S transferase
P1 promoter region is associated with prostate cancer, occur-
ring in approximately 90% of cancer lesions and 70% of high-
grade PIN lesions. Promoter methylation-mediated inactivation
of this gene, which can detoxify environmental carcinogens, has
been proposed as a prerequisite somatic genome alteration
during prostate carcinogenesis. Attempts to reactivate this or
similar pathways form the basis for novel approaches for
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chemoprevention of prostate cancer, which may be particularly
relevant given the putative role for oxidative stress in the etiolo-
gy of this disease (see Nelson et al., 2001 for discussion).
Other sites of loss/deletion in prostate cancer mainly occur
in the late stages of cancer progression. Genetic inactivation of
such tumor suppressor genes as p53, RB1, p16, and PTEN is
seen most commonly in advanced cases of prostate cancer,
although nonmutational downregulation of these genes, partic-
ularly PTEN, may frequently occur earlier. Furthermore, the
occurrence of pathogenic mutations in these genes in early
prostate cancer may portend a less favorable outcome. As men-
tioned above, agents which target PTEN null prostate cancer
cells have provided an important new avenue for therapeutic
intervention. Gains of Xq and 8q are associated with progres-
sion of prostate cancer, and may reflect selection of cells con-
taining extra copies of AR and c-myc, respectively. Activation of
the wnt/β catenin pathway appears to play an important role in a
subset of prostate cancers and activates or otherwise modifies
androgen action in the prostate (Truica et al., 2000; Chesire et
al., 2002). The KLF6 gene at 10p15 has recently been reported
to be inactivated by mutation and deletion in a high proportion of
primary prostate cancers (Narla et al., 2001).
Regarding a potentially inherited form of prostate cancer,
results from multiple studies provide evidence for aggregation
of prostate cancer in families, and family history of prostate can-
cer remains one of the most consistent risk factors yet identi-
fied. Segregation analyses support the existence of high-risk
alleles for prostate cancer, and twin studies have estimated that
a substantial fraction (over 40%) of prostate cancer has a
genetic component (reviewed by Stanford and Ostrander,
2001). These findings have led to genome-wide searches for
prostate cancer susceptibility alleles in collections of prostate
cancer families. In spite of extensive effort, a prostate cancer
equivalent of BRCA1 or -2 has proved elusive. At least eight dif-
ferent loci have been reported to reach some level of signifi-
cance in linkage studies, and over a dozen more loci have been
implicated over the past six years by multiple groups worldwide
working on this problem. Two candidate prostate cancer sus-
ceptibility genes have been identified by positional cloning
efforts, HPC2/ELAC2 and RNase L (Tavtigian et al., 2001;
Carpten et al., 2002). These genes most likely account for a
small proportion of either hereditary prostate cancer or prostate
cancer in general, with their most important effects possibly
being mediating by common, low penetrance alleles.The pauci-
ty of consistent signals in different genome-wide scans of
prostate cancer families supports the conclusion that the genet-
ics of this disease are quite complex, making the influences of
major genes difficult to detect. This outcome is perhaps not sur-
prising given the high prevalence of prostate cancer and its late
onset, etiologic heterogeneity, and inability to define more
genetically homogeneous subsets of disease. The formation of
a large collaborative group to address these questions provides
reason for optimism in this area (Xu, 2000).
In addition to major gene effects, extensive studies are
underway to identify more common “low penetrance” alleles
which may be important in determining or modifying prostate
cancer risk. The identification of common sequence variants in
the androgen action pathway has implicated both the androgen
receptor and various androgen-metabolizing enzymes as
important candidates in this respect (Ross et al., 1998).
Additional studies investigating genetic variation in DNA repair,
carcinogen metabolism, and inflammation pathways as risk fac-
tors for prostate cancer are underway. While on an individual
basis such genetic variants are of limited use for risk assess-
ment, consistent associations of candidate genes can implicate
novel pathways as etiologic factors. Furthermore, it is possible
that such variants, either alone or in combination with other risk
factors, may be useful to stratify risk for prevention or early
screening studies.
Gene expression studiesNew diagnostic and prognostic
markers
In addition to PSA and PSMA, recent expression studies have
identified a large number of potentially important biomarkers,
which are being investigated for their diagnostic, prognostic,
and therapeutic potential. A sampling of these markers includes
Table 1. Genes associated with prostate cancer
Gene Alteration Status Location
PTEN Somatic mutation Inactivated/downregulated 10q23
p53 Somatic mutation Inactivated 17p13
CTNNB1 Somatic mutation Activated 3p21
AR Somatic mutation Altered specificity Xq12
KLF6 Somatic mutation Inactivated* 10p15
GSTP1 Altered expression- Downregulated in PIN 11q13
and cancer - hypermethylated
HPN, AMACR, TARP, FASN Altered expression- Upregulated 5p12, 19q12, 7p14, 17q25
PDGFR, PIM1, phospho-AKT, Altered expression- Upregulated in high grade 5q31, 6p21, 14q32,22q11,  
phospho-MAPK, c-myc 8q24
AR, NFkB, SRC1, Altered expression- Upregulated in advanced/ Xq12, 4q23, 2p23,
ERBB2, S100P, IGFBP2 hormone refractory disease 17q21, 17q21, 2q33
Kai1, CDH1, MKK4 Altered expression- Downregulated in high 11p11, 16q22, 17p11
grade/metastasis
ELAC2/HPC2,  RNAse L Germline mutation/variation Inactivated 17p11, 1q25
AR, CYPs, hOGG1 Germline variation ? Xq12, multiple, 3p26
CAPB, PCAP, HPC20 Not yet cloned ? 1p36, 1q42, 20q13
*Not yet confirmed.
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hepsin, PSCA, AMACR, TARP, STEAP, PCGEM1, DD3, S100P,
and PIM1 (See Table 1). AMACR, an enzyme involved in β oxi-
dation of fatty acids, appears to be a powerful new marker for
prostate cancer (Jiang et al., 2001). Antibodies to PSCA, a cell-
surface antigen expressed in normal prostate and in prostate
cancer tissues, have demonstrated antitumor activity in
xenograft models of prostate cancer (Saffran et al., 2001).
Finally, the ability to develop a molecular classification system
to identify tumors with poor prognosis or otherwise stratify
tumors for treatment options is a current area of intense interest
(Singh et al., 2002).
Conclusion
The dilemma of prostate cancer presents the clinician and basic
researcher with a number of challenges somewhat unique in
human oncology. Its frequent occurrence, tendency for a long
natural history, common multifocality and morphologic hetero-
geneity, and progression to hormone refractory state are all
poorly understood aspects of this disease. However, the rapid
pace of advances, both technologically and mechanistically,
provides a platform for the systematic cataloging and character-
ization of the normal and cancerous prostate cell phenotype
and underlying genotype. This in turn should set the stage for
highly rational approaches to the development of new preven-
tive, prognostic, and therapeutic strategies, which are urgently
needed for this common malignancy.
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